HLA class I associations with the severity of COVID-19 disease in the United Arab Emirates.
Saved in:
| Title: | HLA class I associations with the severity of COVID-19 disease in the United Arab Emirates. |
|---|---|
| Authors: | Tay GK; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Psychiatry, UWA Medical School, The University of Western Australia, Perth, Western Australia, Australia.; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia., Alnaqbi H; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates., Chehadeh S; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates., Peramo B; Al Ain Fertility Center, Al Ain, United Arab Emirates., Mustafa F; Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Rizvi TA; Department of Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Mahboub BH; College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Department of Pulmonary Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates., Uddin M; Department of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Alkaabi N; Department of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Alefishat E; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan., Jelinek HF; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Center of Heath Engineering Innovation, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates., Alsafar H; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.; Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates. |
| Corporate Authors: | UAE COVID-19 Collaborative Partnership |
| Source: | PloS one [PLoS One] 2023 Sep 14; Vol. 18 (9), pp. e0285712. Date of Electronic Publication: 2023 Sep 14 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0285712 |
